The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder.

The FDA is also evaluating data from the phase 3 DAPA-CKD trial, which tested the drug in chronic kidney disease and was stopped early because of efficacy.